
Please try another search
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Name | Age | Since | Title |
---|---|---|---|
Karen K. McGinnis | 56 | 2020 | Lead Independent Director |
Sean McClain | 34 | 2011 | Founder, CEO, President & Director |
Andreas Busch | 61 | 2022 | Chief Innovation Officer & Member of Scientific Advisory Board |
François Adrianus van Houten | 65 | 2023 | Independent Director |
Daniel A. Rabinovitsj | 60 | 2022 | Independent Director |
Iain B. McInnes | 59 | 2024 | Member of Scientific Advisory Board |
Victor Greiff | - | 2023 | Member of Scientific Advisory Board |
Joseph Sirosh | 56 | 2022 | Independent Director |
Hubert Truebel | - | 2023 | Member of Scientific Advisory Board |
Mary T. Szela | 61 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review